|
Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia Clinical research trials and Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia. Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia clinical trial. Participants typically obtain the most effective healthcare available for their Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia  Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
For Condition: HIV Seronegativity,HIV Infections
Status: Not yet recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , NCHADS - Ministry of Health of Cambodia,NCHECR - University of New South Wales, Australia
Synopsis: Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection. Taking tenofovir DF every day may also prevent HIV infection. This study will determine if taking a tenofovir DF tablet every day is safe and effective in preventing HIV infection. Participants in the study will be sex workers in Phnom Penh, Cambodia.
Details: Cambodia has one of the highest rates of HIV infection in Southeast Asia. At the end of 2002, HIV infection rates among Cambodian sex workers ranged from 14.8% to 28.8%. Tenofovir DF is a nucleotide reverse transcriptase inhibitor (NRTI) that was licensed for the treatment of HIV-1 infection by the United States Food and Drug Administration (FDA) in October 2001. This randomized clinical trial will determine if a daily oral 300 mg dose of tenofovir DF is safe and effective in preventing HIV-1 infection. This is a collaborative study between the University of California, San Francisco, the University of New South Wales, and the Ministry of Health of Cambodia. Nine hundred and sixty HIV uninfected female sex workers in Phnom Penh will be enrolled in the trial. Participants will be randomized to receive either 300 mg of tenofovir DF or placebo daily for 12 months. Participants will be evaluated for rates of HIV infection, adherence to the drug regimen, and changes in risk behaviors. All participants will be monitored throughout the trial for side effects and toxicity. Participants will be involved in the study for 14 months.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - HIV uninfected - Report receiving money or gifts for vaginal or anal sexual intercourse in the year prior to study entry - Able to provide a street address of residence for themselves and two personal contacts who would know their whereabouts during the study period - Normal lab values within 14 days of study entry - Ability to understand spoken Khmer - Willing and able to provide written informed consent Exclusion Criteria - Pregnant or breast-feeding - Previously diagnosed active or serious infections - Certain medications - Active alcohol or drug abuse that could interfer with the study - Previously diagnosed malignancies other than basal cell carcinoma - Any other condition that, in the opinion of the study officials, would preclude informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Total Enrollment: 960
Location and Contact Information:
Overall Study Official:
KimberlyShafer, Principal Investigator,
NCAHDS
Phnom Penh, ,
Cambodia
Soleak Sim 12 82 06 92
Additional Information:
Study ID Numbers: 1 U01 AI054241-01;
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00078182
Other Hiv Seronegativity Studies:
1. The Use of Bacteriophage phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo
2. A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex
3. A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3
4. The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine
5. A Study of BufferGel in Women
Related Studies:
Other HIV Seronegativity Clinical Trials
Other Clinical Trials
Other Phnom Penh Clinical Trials
Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
|
|
|
|
|
|
|
|
